Dr. Mokrzycki received her B.S. from Boston College, M.D. from the University of Vermont College of Medicine, and a Masters of Science in Clinical Research from the Albert Einstein College of Medicine. She completed an Internal Medicine Residency and Fellowship at the University of Connecticut Health Science Center in Farmington, CT.
Dr Mokrzycki served on the Program Committee Member for the National Kidney Foundation (NKF) for 2 years, and on Faculty for the Therapeutic Apheresis Academy (TAA) for 5 years, which is held annually at the University of Virginia College of Medicine. She has been an invited speaker and/or chaired sessions at the American Society of Nephrology, NKF, TAA, the American Society of Diagnostic and Interventional Nephrology (ASDIN) and VEITH symposium. Dr. Mokrzycki is one of the founding members of the North American Vascular Access Society, which is a consortium of nephrologists in the United States and Canada with a common research interest in improving outcomes associated with hemodialysis vascular access.
Dr Mokrzycki's research interests have focused primarily on hemodialysis vascular access related complications, specifically, complications associated with tunneled catheter use such as infection/bacteremia/inflammation and dysfunction/thrombosis. Her publications include a randomized controlled trial of low dose warfarin to prevent hemodialysis catheter thrombosis, and a study of catheter bacteremia in HIV hemodialysis patients. She is the recipient of a grant from the AETNA Foundation to study the effect of a multidisciplinary team approach to improve outcomes associated with catheter bacteremia in hemodialysis patients. Dr Mokrzycki participated in a large NIH trial that reported on MYH9 as a major-effect risk gene for focal and segmental glomerulosclerosis (FSGS)
Other areas of research include complications associated with therapeutic apheresis procedures, and the use of plasmapheresis to remove digoxin-Antibody complexes in ESRD, outcomes associated with heparin-free dialysis, reverse transcriptase inhibitor associated lactic acidosis, protein losses associated with continuous renal replacement therapies (CVVH), the epidemiology of HIV associated nephropathy in the Bronx.
- Mokrzycki MH, Yamase H, Kohn OF. Renal malacoplakia with papillary necrosis and renal failure. Am J Kidney Dis 19:587-91, 1992.
- Mokrzycki MH, Kaplan AA. Therapeutic Plasma Exchange: Complications and management. Am J Kidney Dis 23:817-27, 1994.
- Mokrzycki MH, Rickles F, Kaplan AA, Kohn OF. Thrombotic thrombocytopenic purpura in pregnancy: Successful treatment with plasma exchange. Blood Purif 13:271-82, 1995.
- Posner L, Mokrzycki MH. Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use. Am J Nephrol 16:339-43,1996.
- Kerr A, Spector J, Mokrzycki MH, Blau S, Simon R. V
asodilator provocation of occult urinar
y tract hemorrhage. J Trauma 40:152-4, 1996.
- Mokrzycki MH, Kaplan AA. Protein losses in continuous renal replacement therapies. J Am Soc Nephrol 7:1-5, 1996.
- Mokrzycki MH, Patel K, Oo T. Human Immunodeficiency Virus-Associated Nephropathy in the Bronx: Low Prevalence in a Predominantly Hispanic Population. Am J Nephrol 18: 508-512,1998.
- Mokrzycki MH, Harris C, May H, Laut J, Palmisano J. Lactic acidosis associated with stavudine (d4T): Report of 5 cases. Clin Inf Dis 30:198-200, 2000.
- Mokrzycki MH, Schroppel B, von Gersdorff G, Rush H, Zdunek M, Feingold R. Tunneled cuffed catheter associated infections in hemodialysis patients seropositive for the human immunodeficiency virus. J Am Soc Nephrol 11:2122-2127, 2000.
- Barisoni L, Mokrzycki MH, Sablay L, Nagata M, Yamase H, Mundel P. Podocyte cell cycle regulation and proliferation in collapsing glomerulopathies. Kidney Int 58:137-143, 2000.
- Zdunek MP, Mitra A, Mokrzycki MH. Plasma exchange for the removal of digoxin-specific antibody fragments in renal failure: Timing is important for maximizing clearance. Am J Kidney Dis 36:177-183, 2000.
- Solomon N, Mokrzycki MH. Levofloxacin-associated allergic interstitial nephritis. Clin Nephrol 54:356, 2000.
- Mokrzycki MH, Jean-Jerome K, Rush H, Zdunek MP, Rosenberg SO. A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. Kidney Int 59:1935-1942, 2001.
- Swiatecka-Urban A, Mokrzycki MH, Kaskel F, Da Silva F, Denamur E. Novel WT1 mutation (C388Y) in a female child with Denys-Drash syndrome. Pediatr Nephrol 16:627-630, 2001.
- Mokrzycki MH, Singhal A. Cost-Effectiveness of Three Strategies of Managing Tunneled-Cuffed Hemodialysis Catheters (TCC) in Clinically Mild or Asymptomatic Bacteremias. Nephrol Dial Transpl 17(12): 2196-203, 2002.
- Negulescu O, Coco M, Croll J, Mokrzycki MH. Large atrial thrombus formation associated with tunneled cuffed hemodialysis catheters. Clin Nephrol 59(1):40-6, 2003.
- Orloff M, Iyengar SK, Winkler CA, Goddard KAB, Dart RA, Ahuja TS, Mokrzycki MH, Briggs WA, Korbet SM, Kimmel PM, Simon EE, Trachtman H, Vlahov D, Michel DM, Berns JS, Smith MC, Schelling JR, Sedor JR, Kopp JB. Variants in the Wilms’ tumor gene are associated with focal segmental glomerulosclerosis in the African American Population. Physiol Genomics 21:212-221, 2005
- Golestaneh L, Laut J, Rosenberg S, Zhang M, Mokrzycki MH. Favourable outcomes in episodes of Pseudomonas bacteremia when associated with tunneled cuffed catheters (TCC) in chronic hemodialysis patients. Nephrol Dial Transplant. May;21(5):1328-33,2006.
- Mokrzycki MH, Zhang M, Cohen H, Golestaneh L, Laut JM, Rosenberg SO. Tunneled Hemodialysis Catheter Bacteremia: Risk factors for bacteremia recurrence, infectious complications and mortality. Nephrol Dial Transplant. 21(4):1024-31,2006.
- Mokrzycki MH, Zhang M, Golestaneh L, Laut J, Rosenberg SO.A randomized controlled trial comparing two management models for the treatment of tunneled cuffed catheter (TCC) bacteremia: A collaborative team model versus usual physician-managed care. Am J Kidney Dis 48(4):587-95, 2006.
- McKenzie LM, Hendrickson, SL, Briggs WA, Dart RA, Korbet SM, Mokrzycki MH, Kimmel PL, Ahuja TS, Berns JS, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Cho M, Zhou YC, Binns-Roemer E, Kirk GD, Kopp JB, Winkler CA. NPHS2 variation in sporadic focal segmental glomerulosclerosis. J Am Soc Nephrol 18(11): 2987-95, 2007
- Mokrzycki MH. Use of prophylactic topical or intraluminal antibiotics for hemodialysis catheters. Nat Clin Pract Nephrol 4(9):478-9, 2008.
- Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, Mokrzycki MH, Schelling JR, Simon E, Trachtman H, Vlahov D, Winkler CA. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 40 (10):1175-84, 2008.
- Sachdeva M, Bitzer M, Mokrzycki MH. Vascular access type and changes in inflammatory markers in incident dialysis patients: a pilot study. J Vascular Access 10(3):174-179, 2009.
- Golestaneh L, Gofran A, Mokrzycki MH, Chen JL. Removal of vancomycin in sustained low-efficiency dialysis (SLED): a need for better surveillance and dosing. Clin Neph 72 (4):286-291.
- Okafor C, Ward DM, Mokrzycki MH, Weinstein R, Clark P, Balogun RA. Introduciton and overview of therapeutic apheresis. J Clin Apheresis, 2010.
- Lok CE, Mokrzycki MH. Advances in Hemodialysis Catheter-related Infection. U.S. Nephrol, 2010.
- Mokrzycki MH, Lok CE. Traditional and nontraditional strategies to optimize catheter function: Go with more flow. Kidney Int, 2010.
- Lok CE, Mokrzycki MH. Update 2010: Catheter-related Infection in Hemodialysis Patients. Kidney Int. 2010.
- Lok CE, Mokrzycki MH. Prevention and management of catheter-related infection in hemodialysis patients. Kidney Int. 2010;79(6):587-98.
- Mokrzycki MH, Balogun RA. Therapeutic Apheresis: a review of complications and recommendations for prevention and management. J Clin Apher 2011:26(5):243-8.
- Lee T, Mokrzycki MH, Moist L, Maya I, Vazquez M, Lok CE; North American Vascular Access Consortium. Standardized definitions for hemodialysis vascular access. Semin Dial 2011;24(5):515-24.
- Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, Mokrzycki MH, Kimmel PL, Limous S, Ahuja TS, Berns JS, Fryc J, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Vlahov D, Pollack M, Winkler CA. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-Associated nephropathy. J Am Soc Nephrol 2011;22(11):2129-37.
- Sachdeva M, Hung A, Kovalchuk O, Bitzer M, Mokrzycki MH. The initial vascular access type contributes to inflammation in incident hemodialysis patients. Int J Nephrol Volume 2012; (2012) Article ID: 917465.
- Lee T, Lok C, Vazquez M, Moist L, Maya I, Mokrzycki M. Minimizing hemodialysis catheter dysfunction: An ounce of prevention. Int J Nephrol; Volume 2012 (2012), Article ID: 170857.
- Golestaneh L, Mokrzycki MH. Vascular Access in Therapeutic Apheresis: Update 2013. J Clin Apheresis. 2013: 28(1):64-72.
More Information About Dr. Michele Mokrzycki
Montefiore Medical Center
Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.